Cart
sales@molnova.com
Home - Products - Angiogenesis - FGFR - Pemigatinib (INCB054828)

Pemigatinib (INCB054828)

CAS No. 1513857-77-6

Pemigatinib (INCB054828)( INCB054828 )

Catalog No. M21751 CAS No. 1513857-77-6

Pemigatinib (INCB054828) is an orally active, selective FGFR inhibitor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 93 In Stock
5MG 92 In Stock
10MG 147 In Stock
25MG 274 In Stock
50MG 419 In Stock
100MG 556 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    Pemigatinib (INCB054828)
  • Note
    Research use only, not for human use.
  • Brief Description
    Pemigatinib (INCB054828) is an orally active, selective FGFR inhibitor.
  • Description
    Pemigatinib (INCB054828) is an orally active, selective FGFR inhibitor with IC50s of 0.4 nM, 0.5 nM, 1.2 nM, 30 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively. Pemigatinib has the potential for cholangiocarcinoma.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    INCB054828
  • Pathway
    Angiogenesis
  • Target
    FGFR
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1513857-77-6
  • Formula Weight
    487.5
  • Molecular Formula
    C??H??F?N?O?
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO : 25 mg/mL (51.28 mM; ultrasonic and warming and heat to 60°C)
  • SMILES
    CCN(C(N(C(C(F)=C(OC)C=C1OC)=C1F)C2)=O)C(C2=CN3)=C4C3=NC(CN5CCOCC5)=C4
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Arudra K, et al. Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor. J Cutan Pathol. 2018 Oct;45(10):786-790. 2. Roskoski R Jr, et al. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder. Pharmacol Res. 2020 Jan;151:104567. 3. Krook MA, et al. Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy. Cold Spring Harb Mol Case Stud. 2019 Aug 1;5(4).
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • FGFR2-IN-2

    FGFR2-IN-2 is a specific FGFR2 inhibitor that inhibits FGFR1, FGFR2, and FGFR3, and can be used in the study of cancer and cardiovascular disease.

  • BLU-554

    BLU-554 (Fisogatinib, BLU554) is a novel potent, highly selective and orally bioavailable inhibitor of FGFR4 designed for hepatocellular carcinoma (HCC) with FGFR4 pathway activation.

  • Sucralfate

    Sucralfate is a cytoprotective agent, an oral gastrointestinal medication primarily indicated for the treatment of active duodenal ulcers.

Sign In Join Free